Pulse 探索 nav.journalClub 辩论趋势研究者期刊

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

首页探索 nav.journalClub 趋势

⌘+K

Dual Immunization Against RSV With RSVpreF and Nirsevimab | Synapse

May 20, 2026JAMA Pediatrics0 citationsOpen Access

View Full Paper

Dual Immunization Against RSV With RSVpreF and Nirsevimab

LTLudovic TréluyerCenter for the Study of Democracy MBMarion BertrandConservatoire National des Arts et Métiers AGA. GabetPreventive Cardiology

Key Points

The study aims to describe the rate of RSV-associated hospitalizations among infants receiving both RSV-preF vaccination and nirsevimab.
Cohort design focusing on infants in France
Data collected during the 2024-2025 RSV season
Infants received both maternal RSV-preF vaccination and nirsevimab
Higher rates of RSV-related hospitalizations noted in the cohort study
Vaccination and nirsevimab use linked to reduced severity of RSV infections
Findings highlight the potential for enhanced infant protection against RSV

Abstract

This cohort study aimed to describe RSV-associated lower respiratory tract infection hospitalizations among infants in France who received both maternal RSV-preF vaccination and nirsevimab during the 2024-2025 RSV season.

问 AI

Like

Bookmark

Share

View Full Paper

问 AI

Like

Bookmark

Share

View Full Paper

Cite This Study

Tréluyer et al. (Mon,) studied this question.

synapsesocial.com/papers/6a0d5000f03e14405aa9b847 https://doi.org/https://doi.org/10.1001/jamapediatrics.2026.1346